OrbiMed is a global investment firm exclusively focused on the healthcare sector, investing in companies across biopharmaceuticals, medical technologies, medical devices, diagnostics, and healthcare IT and services. Their strategy involves investing across the entire industry lifecycle, from seed-stage ventures to large public companies, utilizing public equity, private equity, and private credit/royalty strategies.
74% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $120.2M (across 96 rounds with reported amounts).
Portfolio
98
Fund Size
$20B
Top Stage
Series B
Last 12 Mo
18
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
98 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| SSpectronRx | Series C | $85M | Apr 2026 |
| SStairMed | Growth | — | Apr 2026 |
 Pinnacle Medicines | Series B | $89M | Mar 2026 |
 Congruence Therapeutics | Series B | $39.5M | Mar 2026 |
 Prolynx | Series A | $70M | Dec 2025 |
 BlossomHill Therapeutics | Series B | $84M | Dec 2025 |
 Aspen Neuroscience | Series C | $115M | Nov 2025 |
 Braveheart Bio | Series A | $185M | Nov 2025 |
 Electra Therapeutics | Series C | $183M | Oct 2025 |
 Sparrow Pharmaceuticals | Series B | $95M | Sep 2025 |
| MMondego Bio | Series A | — | Sep 2025 |
 Epigenic Therapeutics | Series B | $60M | Sep 2025 |
 Treeline Biosciences | Series A | $200M | Sep 2025 |
 Charm Therapeutics | Series B | $68.5M | Sep 2025 |
| LLeal Therapeutics, Inc. | Series A | $30M | Aug 2025 |
| PProVerum | Series B | $68.6M | Aug 2025 |
 ProVerum Limited | Series B | $80M | Aug 2025 |
 Alpheus Medical, Inc. | Series B | $52M | May 2025 |
 Curevo Vaccine | Series B | $110M | Mar 2025 |
 Garuda Therapeutics | Series A | $50M | Mar 2025 |
| PPulnovo Medical | Series C | $100M | Mar 2025 |
 Helicore Biopharma Inc. | Series A | $65M | Jan 2025 |
| WWindward Bio | Series A | $200M | Jan 2025 |
| VVerdiva Bio | Series A | $410M | Jan 2025 |
| RRAPT Therapeutics, Inc. | Series D | $150M | Dec 2024 |
Page 1 of 4
Top Co-Investors
RA Capital Management19 shared
Logos Capital9 shared
Alexandria Venture Investments8 shared
Cormorant Asset Management7 shared
Invus7 shared
ARCH Venture Partners6 shared
Lilly Asia Ventures6 shared
F-Prime Capital6 shared
Foresite Capital6 shared
Novo Holdings6 shared
Sequoia Capital5 shared
Janus Henderson Investors4 shared
Novartis Venture Fund4 shared
Khosla Ventures4 shared
Atlas Venture4 shared
SR One4 shared
Rock Springs Capital4 shared
T. Rowe Price Associates, Inc.4 shared
Redmile Group4 shared
Last updated: 12 April 2026